Pramodini Medicare’s IPO closed with a total subscription of 3.59x by the end of Day 3 on 14-08-2026. The issue witnessed a dramatic momentum shift in the final hours, with Non-Institutional Investors (NII), specifically high-net-worth individuals (bHNI), surging 688.7% intraday from 0.53x to 4.18x. Qualified Institutional Buyers (QIB) also strengthened their position, rising from 1.81x to 3.57x. With the window now closed, the focus shifts to allotment processing for the oversubscribed issue.

Final Subscription Status

The final numbers reflect a robust pickup in NII and QIB participation during the last trading hours of Day 3, pushing the overall multiple well above the fully subscribed mark.

Category-wise Breakdown

• QIB: Institutional investors increased their subscription from 1.81x to 3.57x (+97.2%) on the final day, indicating growing confidence in the diagnostic services model.
• NII: High-net-worth individuals (bHNI) showed explosive late-stage activity, jumping from 0.53x to 4.18x (+688.7%) on Day 3. Small HNIs (sHNI) also increased participation to 4.18x.
• Retail: There was no participation from retail investors throughout the subscription period.

Subscription Progression

The table below highlights the daily progression of the subscription multiples.

Intra-day timeline on 14-08-2026

About the Company

Pramodini Medicare is a diagnostic service provider in India offering technology-enabled diagnostic services including radiology, clinical laboratory, and nuclear medicine services. Founded in 2000, the company operates through four key models: Public Private Partnership, Private Private Partnership, Strategic Partnership with PSUs, and Private Centres. As of the filing date, it operates 16 diagnostic centres across 7 states and 14 cities in India. The company is led by Dr. Chalasani Kuldeep Kumar (MD) and Dr. Chalasani Kavitha (CEO).

Financial Highlights

The company has demonstrated consistent revenue growth over the last three years.

Revenue grew from ₹35.23 crores in FY 2024 to ₹62.29 crores in FY 2026. Total profit increased from ₹6.93 crores to ₹17.38 crores over the same period.

Objects of the Issue

• Capital Expenditure: ₹45.15 crores to purchase and install medical equipment across existing centres in Hubli, Manjeri, and Vijayawada, and establish a new centre in Bangalore.
• General Corporate Purposes: Funds for evaluating inorganic growth opportunities through mergers and acquisitions and meeting general corporate expenses.

Risk Factors

• Dependence on Government PPP Arrangements: 54.19% of revenue is derived from Public Private Partnership arrangements; non-renewal or payment delays could impact operations.
• Heavy Concentration on Radiology Services: 97.05% of revenue comes from radiology services, exposing the company to capital-intensive equipment risks.
• Geographic Revenue Concentration: 61.90% of revenue is derived from Andhra Pradesh, making the business vulnerable to regional economic slowdowns.

What's Next

• Allotment Date: 2026-08-17
• Listing Date: 2026-08-19
• Basis of Allotment: Since the issue is oversubscribed, allotment will be made on a pro-rata basis for all categories except QIB, where it may be discretionary or pro-rata depending on SEBI guidelines.

Pramodini Medicare IPO opened for subscription today, marking the beginning of its public offering journey. Investors can now apply for the shares within the specified price band as the company seeks to raise capital through this initial public offering.

Subscription Status

On Day 1, the Pramodini Medicare IPO recorded a total subscription of 0.75 x. Qualified Institutional Buyers (QIBs) showed the highest interest among investor categories, subscribing to 1.81 x of their quota. Non-Institutional Buyers (bHNI) subscribed to 0.26 x, while Non-Institutional Buyers (sHNI) accounted for 0.15 x. Retail investors and Employees category subscriptions were reported at 0 x on the first day.

About the Company

Pramodini Medicare is entering the public markets with an issue size ranging from ₹396000 to ₹500000. The company operates in the healthcare sector, aiming to leverage the capital raised from this IPO for its business operations and growth initiatives. Key financial details and broader operational metrics are outlined in the offer documents filed with regulators.

Offer Details

The IPO is priced with a floor price of ₹110.00000 and a ceiling price of ₹118.00000. The minimum bid quantity required for application is 2400 units. The issue size is structured between a minimum of ₹396000 and a maximum of ₹500000. Investors are advised to check the official allotment portal and exchange websites for further updates on the subscription timeline and listing details.